about
Inflammatory bowel disease epidemiologyThe Faroese IBD Study: Incidence of Inflammatory Bowel Diseases Across 54 Years of Population-based Data.Fecal Calprotectin Measured By Patients at Home Using Smartphones--A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease.Inflammatory bowel diseases in Faroese-born Danish residents and their offspring: further evidence of the dominant role of environmental factors in IBD development.Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel diseaseEhealth monitoring in irritable bowel syndrome patients treated with low fermentable oligo-, di-, mono-saccharides and polyols diet.Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort.Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet.Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome.Rejuvenating UEG: The Young Talent Group and the Young GI NetworkPolymorphisms in the Toll-Like Receptor and the IL-23/IL-17 Pathways Were Associated with Susceptibility to Inflammatory Bowel Disease in a Danish Cohort.The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease.Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature.The epidemiology of inflammatory bowel disease.The organisation and needs of young sections belonging to UEG National Societies: Results of a Europe-wide survey.Occurrence of anaemia in the first year of inflammatory bowel disease in a European population-based inception cohort - An ECCO-EpiCom study.The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study.Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy.Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases.European Crohn's and Colitis Organisation Topical Review on Environmental Factors in IBD.The complexity of evaluating and increasing adherence in inflammatory bowel disease.Using eHealth strategies in delivering dietary and other therapies in patients with irritable bowel syndrome and inflammatory bowel disease.Young GI Angle: What makes for a good mentor?Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort.European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ('Exit Strategies') in Inflammatory Bowel Disease.Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease.E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach.Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort.Health care and patients' education in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study.Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study.Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort.Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment.Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort.eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with inflammatory bowel disease--an ECCO-EpiCom study.Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study.Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index.Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis.Defining success in treating patients with inflammatory bowel disease.
P50
Q22242717-3D865B71-5C93-4708-BA93-CCC56C3A6C75Q31051199-C468679A-1B69-4335-AA70-A62B1C62CD32Q33445756-341584AE-92A8-48BD-8015-DC4F35254C53Q33578389-8E763872-A8D2-40AD-9745-0DC1AFA259A3Q33696448-78F6DD00-6C22-47C2-B4D5-4EAB37B24D7EQ33718378-DBA208BC-322B-4E65-AC67-98D3B4B37DE3Q33817102-BE30F3E2-FD13-4380-A2F8-96D1CF7BD7F7Q34522949-D10C4E0F-7EE2-4CF9-93CE-7A4000A1FD46Q34552117-94D4D9AA-6774-446A-8865-6277162CF1D0Q35044240-B5CAFA1A-5EE2-44A8-87AD-17176DE38693Q35876578-35786CF0-7B84-4121-9D45-110F5C89718BQ37118470-10A16D6E-857F-43EE-B1E1-941CAC4E6AC6Q38222053-7F9E0395-A8C5-4AE9-86D9-98A8BD9C7096Q38357796-B4373B46-A06F-49AC-B0EB-70D1999720A2Q38641376-D79D1DC1-B92C-495E-9BAA-ED64B991883BQ38748245-4DA94C7A-C38E-4B9F-8352-5C98AB8DFA5AQ38946940-2C67653B-3154-4C7F-A71E-5A53536E776CQ38990031-EC41102F-B543-40A6-B28C-BD5E5FD20F91Q39031811-3E61F329-DD19-4607-AAB7-11DC57776388Q39063326-1AA2C0D7-5428-40B0-A80E-BA0BA702C4D3Q39152590-F11D7835-9E1D-478B-9C21-145EDE8537C9Q39154386-B01099BB-B02A-4648-B460-2AF758A8ED57Q39384342-F11015D0-917A-4B00-9DBB-5EF9E07649BDQ40856508-D2AC8245-CDE4-4EEB-B730-B3CC4E8D0442Q41990807-2F284FF2-6981-4668-AF13-D905CB5C6B02Q42657495-B4D3D3A7-A8B0-4E63-94FB-2DE0788664F4Q42821527-FD3B74C2-5F83-4294-BD73-39CA9A959470Q43525998-B5297328-A32C-4254-BD6F-AFDC86A68276Q44295532-88F1A5ED-9E6D-4B35-A4A0-D825676CF897Q44332424-E1C03945-84C1-415A-8A2A-6857F30BE2FFQ45830165-739C20D3-C40D-4E43-A8C9-BDDF2C28C2E5Q45905337-2B17126E-5B55-4BB2-96A0-35B37F66E37AQ45960133-D6771762-A687-4E91-9EC3-6486B6EF0B53Q47769305-274F5966-3E39-4223-A3DA-F31A77CCDF89Q48064807-E22BEB61-E2E2-4272-A7BA-0E0C4392FA48Q48085176-8261C4DF-51DB-4503-93CF-6554E6B12286Q48177694-979A7354-77FD-4918-AA6A-CDC83D5EB70EQ48218369-4F1D0F83-CA00-460E-AAF0-04AB7BB9BDAAQ48223667-C0334EFF-B778-4610-B81E-27C7CC9CF720Q48295328-F0BE9E3C-23F5-4535-9032-601A6BAA0B48
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Johan Burisch
@ast
Johan Burisch
@en
Johan Burisch
@es
Johan Burisch
@nl
Johan Burisch
@sl
type
label
Johan Burisch
@ast
Johan Burisch
@en
Johan Burisch
@es
Johan Burisch
@nl
Johan Burisch
@sl
prefLabel
Johan Burisch
@ast
Johan Burisch
@en
Johan Burisch
@es
Johan Burisch
@nl
Johan Burisch
@sl
P106
P21
P31
P496
0000-0002-3312-5139
P569
2000-01-01T00:00:00Z